

# The Journey of ADCs in Metastatic NSCLC: Past, Present and Future

**Friday 13 September 2024 | 18:00–19:30 CEST**

Alicante Auditorium, Hall 3, Fira Barcelona Gran Via, Barcelona, Spain

## AGENDA

18:00–18:05

**Welcome and Introduction – The Journey of ADCs in Metastatic NSCLC: Past, Present and Future**



**Prof. Sanjay Popat (UK)**

Consultant Medical Oncologist at The Royal Marsden and Professor of Thoracic Oncology at The Institute of Cancer Research, London, UK

18:05–18:20

**The Unmet Needs and Limitations of Current Treatment Options in Metastatic NSCLC**



**Prof. David Planchard (France)**

Thoracic Oncologist and Head of Thoracic Pathology Committee at Institut Gustave Roussy, Villejuif, France

18:20–18:50

**ADCs in Metastatic NSCLC**



**Prof. Marina Garassino (USA)**

Professor of Medicine and Thoracic Program Director at The University of Chicago, IL, USA

18:50–19:15

**The Future of ADCs in Lung Cancer**



**Dr. Melissa Johnson (USA)**

Medical Oncologist and Director of Lung Cancer Research at Sarah Cannon Research Institute, Nashville, TN, USA

19:15–19:30

**Panel Discussion and Q&A**

All Faculty, Facilitated by Prof. Sanjay Popat (UK)

ADC, antibody-drug conjugate; NSCLC non-small cell lung cancer

This non-promotional symposium is sponsored and organised by Gilead. Intended for health care professionals only for scientific exchange.

The purpose of this symposium is scientific exchange. The audience is encouraged to actively participate throughout the symposium by using the voting system after each presentation and during the live Q&A.

GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. ©2024 Gilead Sciences, Inc. All rights reserved.

June 2024 | IHQ-UNB-5933



Oncology

